Subsequently, pembrolizumab (an anti–PD–1 antibody) and atezolizumab (an anti–PD–L1 antibody) were shown, respectively, to be appropriate 2nd–line treatments for advanced NSCLC by the KEYNOTE–010 and POPLAR trials (34, 35). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.